Phase II trial of high-dose continuous infusion 5-fluorouracii with allopurinol modulation in colon cancer

Frederick R. Ahmann, Harinder Garewal, Bernard R. Greenberg

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Twenty patients with metastatic colon cancer without prior chemotherapy received 2 g/m2 of 5-fluorouracil (5-FU) infused over 24 h for 5 days preceded by allopurinol 900 mg orally for 1 week and then continued during, and for 1 week after the infusion was completed. Fourteen patients were evaluable for both response and toxicity. One patient (14%) achieved a partial response lasting 2 months. No significant hematologic toxicity was seen but 18 of 19 patients evaluable for toxicity developed mucositis resulting in dose reductions in 3 patients and refusal of a second course by 2 additional patients. 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule.

Original languageEnglish (US)
Pages (from-to)83-85
Number of pages3
JournalOncology (Switzerland)
Volume43
Issue number2
DOIs
StatePublished - Jan 1 1986

Keywords

  • 5-fluorouracil
  • Allopurinol
  • Colon cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of high-dose continuous infusion 5-fluorouracii with allopurinol modulation in colon cancer'. Together they form a unique fingerprint.

  • Cite this